The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Exclusion Criteria

• •7. Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal, not clinically significant or with abnormalities consistent with obesity
• •8. Is able to read, understand, and sign the informed consent forms (ICF) and, when applicable, an authorization to use and disclose protected health information form (consistent with Health Insurance Portability and Accountability Act of 1996 \[HIPAA\] legislation), communicate with the investigator, and understand and comply with protocol requirements.
• •1. Diagnosis of diabetes or on a diabetes medication
• •2. HbA1c ≥6.5% at Screening/Visit 1 (Day-7/Week-1)
• •3. Severe renal impairment (eGFR \< 45 mg/mL/1.73 m2) and/or patients with acute or chronic metabolic acidosis. Acidosis is defined as \>25mmol/L computed without K.
• •Normal is 8- 16, but acidosis is \>25
• •4. Use of any of the following medications in the eight weeks prior to entering screening for study participation and during the study:
• •1. Use of any anti-diabetes medication including metformin and any combination drug that contains metformin
• •2. Sildenafil
• •3. Tadalafil
• •4. Vardenafil
• •5. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine)
• •6. Riociguat (guanylate cyclase stimulant)
• •7. Alpha blockers
• •8. Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine patches)
• •9. Potent CYP3A4 inhibitors (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir)
• •10. All antihypertensive medications
• •11. Medications associated with weight changes
• •* Drugs approved for the treatment of obesity
• •* Cypropheptadine or medroxyprogesterone
• •* Atypical anti-psychotic drugs
• •* Tricyclic antidepressants
• •* Lithium, MAO's, glucocorticoids
• •* SSRI's or SNRI's
• •* Antiepileptic drugs
• •* Systemic corticosteroids
• •* Stimulants e.g. amphetamines
• •12. Any dietary supplement that is labeled for weight management or maintenance of healthy weight
• •5. Diagnosis or evidence of eating disorders
• •6. ≥ 5% weight change in the last 3 months
• •7. Subjects who have had bariatric surgery
• •8. An infection requiring antibiotic treatment within the last 30 days
• •9. Any chronic inflammatory disease, e.g. inflammatory bowel disease rheumatoid arthritis, vasculitis, systemic lupus erythematosus
• •10. Diseases interfering with metabolism (including metabolism of branched chain amino acids) and/or ingestive behavior (myxedema, Cushing's disease, diabetes, schizophrenia, major psychoses, maple syrup urine disease, unmanaged depression etc.)
• •11. History of alcohol abuse (defined ≥ 21 drinks per week for males and \> 14 drinks per week for females), within the past 3 months or failure on urinary drug screen
• •12. History of substance abuse (including alcohol abuse as defined above) in the past 12 months or a positive screen for drugs (opioids without a prescription), including marijuana, of abuse or alcohol at screening.
• •13. Has received any investigational drug within 3 months of Screening.
• •14. Has donated blood within 3 months before Screening or is planning to donate blood during the study (due to HbA1c reading at screening)
• •15. Other medical conditions that may diminish life expectancy to \<2 years, including known cancers
• •16. Have been diagnosed with metastatic carcinomas in the last 5 years
• •17. Has known allergies or hypersensitivity to metformin, sildenafil or leucine
• •18. Have suffered myocardial infarction, stroke, arrhythmia in the last 6 months
• •19. Resting hypotension (BP \<90/50 mmHg) or severe hypertension (BP \>170/110 mmHg) If both or one of the parameters for diastolic or systolic BP is meet
• •20. Cardiac failure or coronary artery disease causing unstable angina
• •21. History or evidence at screening of left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure
• •22. At risk for priapism due to anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease) or other conditions that predispose to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia)
• •23. Clinical evidence of hepatic impairment and/or ALT/AST \>5X ULN
• •24. Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or NuSirt Biopharma.
• •25. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or designee responsible for the conduct of the study).